Cancer Treatment News and Research

RSS

China’s 3rd Annual Asia Scientific Congress programs feature latest updates on cancer

In an effort to curb the cancer rates, the country has adopted evidence-based treatment guidelines and continues to strengthen a number of strategic collaborations with the National Comprehensive Cancer Network® (NCCN®) as demonstrated by several NCCN programs scheduled throughout China this spring.

25 Mar 2010

Bergen research group adopts nanotechnology for cancer research

Professor James Lorens and his team at the University of Bergen's Department of Biomedicine are using nanotechnology to study how to make cells form new blood vessels, both within the patient's body and in the laboratory. In the next phase the team will use this knowledge to investigate the molecular mechanisms that govern the progression of cancer.

24 Mar 2010

RCOG prostate cancer treatment database reaches new milestone

Radiotherapy Centers of Georgia (RCOG), a division of RC Cancer Centers announced today that they have reached a new milestone and recently treated their 12,500th patient for prostate cancer with their ProstRcision® treatment therapy.

24 Mar 2010

Healing Choices study for cancer treatment choice

Recognizing the critically important lapse between the diagnosis and treatment, The Cancer Information Service Research Consortium is conducting a Healing Choices study that will try to determine if receiving a multimedia presentation of medical options helps patients make informed treatment decisions.

24 Mar 2010

Virginia-based medical practice implements CTT's pain therapy medical device

Competitive Technologies, Inc. announced that a premier physician oncology practice based in Virginia has begun using CTT's Calmare® Therapy pain therapy medical device to treat patients suffering from pain related to cancer, under the direction of several medical oncologists.

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Short of specialists and cancer care

Associate Professor Bogda Koczwara, from the Medical Oncology Group of Australia, conducted the survey which found just 19 per cent of all those diagnosed with cancer were receiving chemotherapy.

23 Mar 2010

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study.

22 Mar 2010

Cancer radiotherapy can increase risk of cardiovascular disease later in life

For an as yet unknown reason, cancer radiotherapy can increase the risk of cardiovascular disease later in life, a problem that is growing as more and more people survive their cancer diagnosis. New research from Karolinska Institutet now suggests that sustained inflammation induced by post-radiotherapy changes in the gene expression in the arteries could be the cause.

22 Mar 2010

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

Concord Medical Services Holdings reports 24.3% increase in total net revenues for fourth-quarter 2009

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2009(1), and the appointment of Dr. Hongbin Cai as an independent board member.

18 Mar 2010

Study finds the cost of cancer care is skyrocketing

USA Today: "The cost of cancer treatment is 'skyrocketing' — both for individual patients and the nation, a new analysis shows. From 1990 to 2008, spending on cancer care soared to more than $90 billion from $27 billion. The increase was driven by the rising costs of sophisticated new drugs, robotic surgeries and radiation techniques, as well as the growing number of patients who are eligible to take them, says Peter Bach of New York's Memorial Sloan-Kettering Cancer Cancer, co-author of an analysis in today's Journal of the American Medical Association.

18 Mar 2010

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.

18 Mar 2010

Standardized skin-care guidelines

Given the complexity of cancer treatment, skin care may seem like a small matter. However, a nurse at the James P. Wilmot Cancer Center knew that skin issues were a constant source of anxiety for many patients receiving radiation therapy, and through research she discovered that routine advice was rooted in myth instead of scientific evidence.

18 Mar 2010

SBRT can improve survival rates for patients with inoperable non-small cell lung cancer

Highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to early findings of a Radiation Therapy Oncology Group study published in the March 17 cancer-themed issue of the Journal of the American Medical Association.

18 Mar 2010

McGill researchers pioneer major breakthrough in DNA nanotechnology

A team of McGill Chemistry Department researchers led by Dr. Hanadi Sleiman has achieved a major breakthrough in the development of nanotubes - tiny "magic bullets" that could one day deliver drugs to specific diseased cells.

18 Mar 2010

SBRT doubles rate of primary tumor control compared to conventional radiotherapy

Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.

18 Mar 2010

Novel findings point to new therapeutic approaches for common types of cancer

Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.

18 Mar 2010

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

Enzo Biochem, Inc., a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, announced today a supply and distribution agreement between Enzo Life Sciences and privately-owned Cancer Genetics Inc., a leading producer of nucleic acid products used in genomic research.

18 Mar 2010